Omeros

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Omeros and other ETFs, options, and stocks.

About OMER

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. 

CEO
Gregory A. Demopulos
CEOGregory A. Demopulos
Employees
175
Employees175
Headquarters
Seattle, Washington
HeadquartersSeattle, Washington
Founded
1994
Founded1994
Employees
175
Employees175

OMER Key Statistics

Market cap
1.21B
Market cap1.21B
Price-Earnings ratio
11.37
Price-Earnings ratio11.37
Dividend yield
—
Dividend yield—
Average volume
1.26M
Average volume1.26M
High today
$16.77
High today$16.77
Low today
$16.11
Low today$16.11
Open price
$16.31
Open price$16.31
Volume
190.36K
Volume190.36K
52 Week high
$21.24
52 Week high$21.24
52 Week low
$6.24
52 Week low$6.24

Stock Snapshot

Omeros(OMER) stock is priced at $16.67, giving the company a market capitalization of 1.21B. It carries a P/E multiple of 11.37.

On 2026-10-20, Omeros(OMER) stock traded between a low of $16.11 and a high of $16.77. Shares are currently priced at $16.67, which is +3.4% above the low and -0.6% below the high.

Omeros(OMER) shares are trading with a volume of 190.36K, against a daily average of 1.26M.

In the last year, Omeros(OMER) shares hit a 52-week high of $21.24 and a 52-week low of $6.24.

In the last year, Omeros(OMER) shares hit a 52-week high of $21.24 and a 52-week low of $6.24.

OMER News

Simply Wall St 2d
Why Omeros Stock Is Down 13.8% And What's Next After EU Drug Rejection

Omeros reported that the European Medicines Agency’s CHMP upheld its negative opinion on the marketing authorization application for narsoplimab in TA TMA after...

Why Omeros Stock Is Down 13.8% And What's Next After EU Drug Rejection
Simply Wall St 3d
Is Omeros Undervalued After The EMA Upheld Its Narsoplimab Setback? - Simply Wall Street

...

Is Omeros Undervalued After The EMA Upheld Its Narsoplimab Setback? - Simply Wall Street
Benzinga 4d
Omeros Stock Sinks on Negative EU Opinion for Narsoplimab, Compassionate-Use Program Ends

Omeros Corporation (NASDAQ:OMER) shares are trading lower Friday after the company announced that the European Medicines Agency’s CHMP issued a negative opinion...

Omeros Stock Sinks on Negative EU Opinion for Narsoplimab, Compassionate-Use Program Ends

More OMER News

TipRanks 4d
Omeros receives negative CHMP opinion on MAA for narsoplimab

Omeros (OMER) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a negative opinion on the company’s mark...

People also own

Based on the portfolios of people who own OMER. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.